http://www.biotechnologynews.net
Tuesday, 6 July 2010
Stirling refines its focus
Stirling Products said its interests will operate through three focused divisions pharmaceutical, healthcare and animal health during the 2011 financial year.
The company said in its year end review that while it would continue its expansion as an integrated global pharmaceutical and healthcare group, Stirlings focus for the coming year would be on the realisation of substantial revenues.
Stirling is also looking forward to the potential partnering of its unique breakthrough inhalation drug delivery platform with a major industry partner.
The company has engaged ex-Cochlear and ResiMed executive Ross Harricks and an ex-IMS Health director to assist with the introduction and commercialisation process.
Stirling expects the commercialisation approach to be finalised by the end of 2011.
Add to My Watchlist
What is My Watchlist?